Management of the primary tumor and limited metastases in patients with metastatic pancreatic cancer

Joseph M. Herman, John P. Hoffman, Sarah P. Thayer, Robert A. Wolff

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations

Abstract

New combinations of cytotoxic chemotherapy have been proven to increase response rates and survival times compared with single-agent gemcitabine for patients with metastatic pancreatic cancer. These responses have been dramatic for a subset of patients, therefore raising questions about the management of limited metastatic disease with surgery or other ablative methods. Similarly, for patients having a complete radiographic response to chemotherapy in the metastatic compartment, whether to consider local therapy in the form of radiation or surgery for the primary tumor is now an appropriate question. Therefore, collaboration among experts in surgery, medical oncology, and radiation oncology has led to the development of guiding principles for local therapies to the primary intact pancreatic tumor for patients with limited metastatic disease and those who have had a significant response after systemic therapy.

Original languageEnglish (US)
Pages (from-to)e29-e36
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume13
Issue number5
DOIs
StatePublished - May 1 2015

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Management of the primary tumor and limited metastases in patients with metastatic pancreatic cancer'. Together they form a unique fingerprint.

Cite this